Trials / Conditions / Influenza Immunisation

Influenza Immunisation

14 registered clinical trials studyying Influenza Immunisation.

Status	Trial	Sponsor	Phase
Completed	Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Ad NCT04451954	Sanofi Pasteur, a Sanofi Company	Phase 1
Completed	Flublok or Fluzone With Advax-CpG55.2 or AF03 NCT03945825	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	2017 A/H7N9 IIV Revaccination NCT03738241	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza NCT03682120	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Development of Childhood Anti-Influenza Immunity NCT03673345	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Completed	2013/2017 H7N9 Prime-Boost Interval NCT03589807	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	H3N2 M2SR in Pediatric Population NCT03553940	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	H5N1 With or Without Topical Aldara in Healthy Adults NCT03472976	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine NCT03058692	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 NCT03318315	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly NCT03312231	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Age and Response to Flu Vaccines NCT03328325	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Terminated	Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination NCT02485639	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Terminated	Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers NCT02385123	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4